Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC)
Copyright © 2021 Elsevier Inc. All rights reserved..
T790M mutation is the most common mechanism of acquired resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). To overcome this resistance, 4-anilinoquinazoline-based irreversible inhibitors afatinib, dacomitinib has been developed. However, the clinical application of these irreversible inhibitors is limited due to its narrow selectivity against L858R/T790M mutant EGFR. In an attempt to develop potent and selective EGFR T790M inhibitors, we have designed and synthesized two series of novel acrylamide linked quinazolines. Among them, compounds 2i (IC50 0.171 µM) and 11h (IC50 0.159 µM) were identified as potent compounds, which displayed selective and potent anti-proliferative activity on gefitinib-resistant cell line NCI-H1975 as compared to the gefitinib and WZ4002 in cellular assay. Furthermore, a molecular dynamic simulation of 11h was carried out to assess the stability to form a complex with the L858R/T790M EGFR Kinase domain, which demonstrated that complex was stable for the 100 ns and form strong crucial covalent binding contacts with the thiol group of Cys797 residue. Finally, satisfactory in silico pharmacokinetics properties of 2i, 11h and 11i compounds were predicted. The synthesized compounds were also evaluated for in vitro cytotoxic activity/hepatotoxicity against HepG2 cell line through MTT assay. The results revealed that compounds exhibited lower cytotoxicity to HepG2 cells.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
---|---|
Enthalten in: |
Bioorganic chemistry - 115(2021) vom: 16. Okt., Seite 105234 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pawara, Rahul [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 30.12.2021 Date Revised 30.12.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.bioorg.2021.105234 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM329429612 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM329429612 | ||
003 | DE-627 | ||
005 | 20231225205112.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.bioorg.2021.105234 |2 doi | |
028 | 5 | 2 | |a pubmed24n1098.xml |
035 | |a (DE-627)NLM329429612 | ||
035 | |a (NLM)34399322 | ||
035 | |a (PII)S0045-2068(21)00611-8 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pawara, Rahul |e verfasserin |4 aut | |
245 | 1 | 0 | |a Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC) |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.12.2021 | ||
500 | |a Date Revised 30.12.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
520 | |a T790M mutation is the most common mechanism of acquired resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). To overcome this resistance, 4-anilinoquinazoline-based irreversible inhibitors afatinib, dacomitinib has been developed. However, the clinical application of these irreversible inhibitors is limited due to its narrow selectivity against L858R/T790M mutant EGFR. In an attempt to develop potent and selective EGFR T790M inhibitors, we have designed and synthesized two series of novel acrylamide linked quinazolines. Among them, compounds 2i (IC50 0.171 µM) and 11h (IC50 0.159 µM) were identified as potent compounds, which displayed selective and potent anti-proliferative activity on gefitinib-resistant cell line NCI-H1975 as compared to the gefitinib and WZ4002 in cellular assay. Furthermore, a molecular dynamic simulation of 11h was carried out to assess the stability to form a complex with the L858R/T790M EGFR Kinase domain, which demonstrated that complex was stable for the 100 ns and form strong crucial covalent binding contacts with the thiol group of Cys797 residue. Finally, satisfactory in silico pharmacokinetics properties of 2i, 11h and 11i compounds were predicted. The synthesized compounds were also evaluated for in vitro cytotoxic activity/hepatotoxicity against HepG2 cell line through MTT assay. The results revealed that compounds exhibited lower cytotoxicity to HepG2 cells | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Acrylamide linked Quinazolines | |
650 | 4 | |a EGFR L858R/T790M | |
650 | 4 | |a MD simulation | |
650 | 4 | |a Non Small-Cell Lung Cancer (NSCLC) | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
650 | 7 | |a Quinazolines |2 NLM | |
650 | 7 | |a Acrylamide |2 NLM | |
650 | 7 | |a 20R035KLCI |2 NLM | |
650 | 7 | |a EGFR protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a ErbB Receptors |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
700 | 1 | |a Ahmad, Iqrar |e verfasserin |4 aut | |
700 | 1 | |a Nayak, Deepika |e verfasserin |4 aut | |
700 | 1 | |a Wagh, Shivani |e verfasserin |4 aut | |
700 | 1 | |a Wadkar, Avinash |e verfasserin |4 aut | |
700 | 1 | |a Ansari, Azim |e verfasserin |4 aut | |
700 | 1 | |a Belamkar, Sateesh |e verfasserin |4 aut | |
700 | 1 | |a Surana, Sanjay |e verfasserin |4 aut | |
700 | 1 | |a Nath Kundu, Chanakya |e verfasserin |4 aut | |
700 | 1 | |a Patil, Chandragauda |e verfasserin |4 aut | |
700 | 1 | |a Patel, Harun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Bioorganic chemistry |d 1986 |g 115(2021) vom: 16. Okt., Seite 105234 |w (DE-627)NLM012846570 |x 1090-2120 |7 nnns |
773 | 1 | 8 | |g volume:115 |g year:2021 |g day:16 |g month:10 |g pages:105234 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bioorg.2021.105234 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 115 |j 2021 |b 16 |c 10 |h 105234 |